Random Forests Screening of Baseline Characteristics to Predict Efficacy and Safety/Tolerability of Aripiprazole in Pediatric Patients with Bipolar I Disorder

Thursday, October 20, 2011

Joan Zhao, Ph.D., Otsuka Pharmaceutical Development and Commercialization Inc., Princeton, NJ

Kiki D. Chang, M.D., Psychiatry, Stanford University School of Medicine, Palo Alto, CA

Eric Youngstrom, Ph.D., University of North Carolina at Chapel Hill, Chapel Hill, NC

Benjamin I. Goldstein, M.D., FRCPC, Ph.D., Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Ron Marcus, M.D., Bristol-Myers Squibb, Wallingford, CT

Robert D. McQuade, Ph.D., Otsuka Pharmaceutical Development and Commercialization Inc., Princeton, NJ

Robert A. Forbes, Ph.D., Otsuka Pharmaceutical Development and Commercialization Inc., Princeton, NJ

Candace Andersson, Ph.D., Bristol-Myers Squibb, Plainsboro, NJ

Diane Ammerman, Pharm.D., Bristol-Myers Squibb, Plainsboro, NJ

Elizabeth Bellocchio, Ph.D., Bristol-Myers Squibb, Sacramento, CA

Maia Miguelez, Ph.D., Department of Medical Affairs, Bristol-Myers Squibb Canada, St-Laurent, QC, Canada

Ray Mankoski, M.D., Ph.D., Bristol-Myers Squibb, Plainsboro, NJ


Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

New Research Poster Presentation 2.18 Random Forests Screening of Baseline Characteristics to Predict Efficacy and Safety/Tolerability of Aripiprazole in Pediatric Patients with Bipolar I Disorder